Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||FGFR3 D764H|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Response Type||no benefit|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 D764H||head and neck squamous cell carcinoma||no benefit||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, Truseltiq (infigratinib) inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764H in culture, however, cells expressing FGFR3 D764H did not demonstrate increased sensitivity to Truseltiq (infigratinib) compared to cells expressing wild-type FGFR3 (PMID: 27053219).||27053219|
|PubMed Id||Reference Title||Details|
|(27053219)||Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.||Full reference...|